Pulmatrix Q1 rev $5.9M, net income $0.8M; PUR1900 study wind down, cash runway into Q1 2026

Pulmatrix, Inc.

2024-Q1 EPS reported $0.23 revenue$5,885,000

Revenue $5.9M (up $4.4M YoY) due to Cipla contract modification catch-up.
Net income $0.8M vs net loss $4.4M in prior year.
Cash $16.3M; expects cash runway into Q1 2026.
PUR1900 Phase 2b stopped (no safety concern); Pulmatrix bears no further dev cost, gets 2% royalty on ex-US sales.
PUR3100 Phase 2-ready; seeking partnership for Phase 2 study.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pulmatrix, Inc. reported three months ended March 31, 2024 results: revenue $5.9 million, net income $0.8 million.

Period: three months ended March 31, 2024
Revenue: $5.9 million
Net income: $0.8 million
Result: reported results

Exact text from the filing

outside the United States. Within the United States, Pulmatrix and Cipla will seek to monetize PUR1900. First Quarter 2024 Financial Results Revenues increased $4.4 million to $5.9 million for the three months ended March 31, 2024, compared to $1.5 million for the three months ended March 31, 2023. The increase is primarily related to a contract modification of the

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Pulmatrix, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018576

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.